Hypertrophic cardiomyopathy: the future of treatment
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.1715
Abstract: Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic disorder most often caused by sarcomeric mutations resulting in left ventricular hypertrophy, fibrosis, hypercontractility, and reduced compliance. It is the most common inherited monogenic cardiac condition, affecting 0.2%… read more here.
Keywords: future treatment; treatment; hypertrophic cardiomyopathy; cardiomyopathy future ... See more keywords
Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions
Sign Up to like & getrecommendations! Published in 2023 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s368590
Abstract: Abstract Hypertrophic cardiomyopathy (HCM) is a condition with abnormal hypertrophy of the left ventricle in the absence of common causes. The most common form involves the basal septum and can lead to obstruction of the… read more here.
Keywords: hypertrophic cardiomyopathy; mavacamten obstructive; obstructive hypertrophic; future directions ... See more keywords